Bafna Pharmaceuticals has rallied over 8% to Rs 32.75 on BSE on reports that the promoters of the company intends to divest their stake from the company.
“US-based generic drug maker Mylan and two Indian pharma companies are in the race to acquire Chennai-based Bafna Pharmaceuticals,” Economic Times report suggests.
Bafna Pharmaceuticals makes indictable, generic drugs and haemoglobin drug 'Raricap'.
Meanwhile, the company on Monday said, it has launched pain management and anti-infective products in the domestic market as it looks to expand presence in these segments.
"The company is expanding its base into pain management and anti-infectives by launching Afenac-P tablets, Afnec Th tablets, Nocaf syrup, Izabof suspension and Izabof 250 and 500 mg tablets," Bafna Pharmaceuticals said in a filing to BSE.
The stock opened at Rs 35.95 and has seen over multiple-fold jump in trading volumes. A combined 551,161 shares have already changed hands on the counter till 0935 hours against an average sub 100,000 shares that were traded daily in past two weeks on BSE and NSE.
“US-based generic drug maker Mylan and two Indian pharma companies are in the race to acquire Chennai-based Bafna Pharmaceuticals,” Economic Times report suggests.
Bafna Pharmaceuticals makes indictable, generic drugs and haemoglobin drug 'Raricap'.
Meanwhile, the company on Monday said, it has launched pain management and anti-infective products in the domestic market as it looks to expand presence in these segments.
"The company is expanding its base into pain management and anti-infectives by launching Afenac-P tablets, Afnec Th tablets, Nocaf syrup, Izabof suspension and Izabof 250 and 500 mg tablets," Bafna Pharmaceuticals said in a filing to BSE.
The stock opened at Rs 35.95 and has seen over multiple-fold jump in trading volumes. A combined 551,161 shares have already changed hands on the counter till 0935 hours against an average sub 100,000 shares that were traded daily in past two weeks on BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%